Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast CancerDaniele Generali, Stephen B. Fox, Alfredo Berruti et al.|Clinical Cancer Research|2006Cited by 244
Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer PatientsAlberto Bottini, Alfredo Berruti, Daniele Generali et al.|Journal of Clinical Oncology|2006Cited by 190
Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer PatientsDaniele Generali, Stephen B. Fox, Gaynor J. Bates et al.|Clinical Cancer Research|2009Cited by 161
Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast CancerDaniele Generali, Stephen B. Fox, Sergio Aguggini et al.|Journal of Clinical Oncology|2008Cited by 116
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancerDaniele Generali, Adrian L. Harris, Stephen B. Fox et al.|Endocrine Related Cancer|2006Cited by 79